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Abstract
Background: Recently, several studies have reported Yokukansan (Tsumura TJ-54), a traditional Japanese medicine, as a
potential new drug for the treatment of Alzheimer’s disease (AD). Endoplasmic reticulum (ER) stress is known to play an
important role in the pathogenesis of AD, particularly in neuronal death. Therefore, we examined the effect of Yokukansan
on ER stress-induced neurotoxicity and on familial AD-linked presenilin-1 mutation-associated cell death.
Methods: We employed the WST-1 assay and monitored morphological changes to evaluate cell viability following
Yokukansan treatment or treatment with its components. Western blotting and PCR were used to observe the expression
levels of GRP78/BiP, caspase-4 and C/EBP homologous protein.
Results: Yokukansan inhibited neuronal death during ER stress, with Cnidii Rhizoma (Senkyu), a component of Yokukansan,
being particularly effective. We also showed that Yokukansan and Senkyu affect the unfolded protein response following ER
stress and that these drugs inhibit the activation of caspase-4, resulting in the inhibition of ER stress-induced neuronal
death. Furthermore, we found that the protective effect of Yokukansan and Senkyu against ER stress could be attributed to
the ferulic acid content of these two drugs.
Conclusions: Our results indicate that Yokukansan, Senkyu and ferulic acid are protective against ER stress-induced
neuronal cell death and may provide a possible new treatment for AD.
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Introduction
Yokukansan (Tsumura TJ-54), a traditional Japanese medicine,
has traditionally been administered to patients who show sym-
ptoms such as nervousness, short-temperedness, irritability,
sleeplessness, twitching of the eyelids and shaking of the limbs. It
has also been administered to infants who suffer from night crying,
restlessness and convulsions. Recently, several clinical reports have
shown that Yokukansan is effective against the Behavioral and
Psychological Symptoms of Dementia (BPSD) and improves daily
living of patients [1–3]. Thus, Yokukansan has been suggested as a
possible new candidate for treating Alzheimer’s disease (AD).
However, no basic research on the clinical effects of Yokukansan
has been conducted.
Many reports have suggested that endoplasmic reticulum (ER)
stress is involved in the pathogenesis of AD, with several studies
showing that the amyloid b protein, which is abundant in the AD
brain, induces ER stress [4–6]. Previous studies from our
laboratory have shown that the familial AD (FAD)-linked
presenilin-1 (PS1) mutation increases the susceptibility to ER
stress and that the presenilin-2 (PS2) splice variant (PS2V),
observed in the sporadic form of AD, also increases the risk of ER
stress [7–12]. These results suggest that ER stress is involved in the
pathogenesis of AD.
ER stress activates both the survival and apoptotic pathways. In
the survival pathway, ER stress induces the transcription of genes
encoding for the ER-resident chaperones such as GRP78/Bip,
GRP94 and protein disulfide isomerase (PDI), which facilitate
protein folding. This induction system is termed the ‘unfolded-
protein response (UPR) [13–16]. By contrast, the representative
gene C/EBP homologous protein (CHOP), also known as growth
arrest and DNA damage-inducible gene 153 (GADD153), is
induced in the apoptotic pathway [16–17]. In addition, we have
revealed the involvement of caspase-4, a protease that is
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in the pathogenesis of AD [18]. The familial AD-linked PS1
mutation accelerates the cleavage of caspase-4, which in turn
activates caspase-3 and caspase-9 without involving the cyto-
chrome-c pathway [19]. These results suggest that the initiation of
caspase-4 cleavage is one of the key events for the pathogenesis of
AD.
In this report, we studied the effect of Yokukansan on ER stress-
induced neurotoxicity and on FAD-linked PS1 mutation (DE9)
associated cell death. We determined that upregulation of
GRP78/Bip expression by Yokukansan, as well as the inhibition
of CHOP induction, results in a reduction of ER stress-induced
cell death and FAD-linked associated cell death. In addition, we
showed that Yokukansan inhibits the activation of caspase-4.
Furthermore, we exhibited that the effects of Yokukansan could be
attributed to the function of Cnidii Rhizoma (Senkyu), a
component of Yokukansan. We determined that the ferulic acid
contained in Senkyu plays an important role for the protective
function of Yokukansan or Senkyu. These results show that
Yokukansan, Senkyu or ferulic acid alone could be a potential
treatment for AD and our findings cast new light on the
development of new therapies for AD.
Results
Yokukansan reduces ER stress-induced neuronal cell
death
We examined the effects of Yokukansan on neuronal cell death
caused by several stresses using the mouse neuroblastoma cell line,
Neuro2a (N2a). Thapsigargin (TG) and hypoxia were used as ER
stress inducers and staurosporine (STS) was used as a mitochondrial
stress inducer. Yokukansan significantly decreased the cell death
caused by TG and hypoxia (Figure 1A and 1B), but did not protect
against STS treatment (Figure 1B). These results indicate that
Yokukansan is effective against ER stress-induced neuronal toxicity
that involves impairment of calcium homeostasis, but not apoptotic
stimuli that do not cause ER stress. Notably, as shown in Figure 1C,
the protective effect of Yokukansan against ER stress-induced cell
death is proportional to the concentration of Yokukansan used.
However, a high dose of Yokukansan showed some toxicity.
Cnidii Rhizoma (Senkyu), a component of Yokukansan,
has a potent protective effect against ER stress-induced
neuronal toxicity
To determine which component of Yokukansan plays a key role
in inducing the protective effect against neuronal cell death
caused by ER stress, we examined the effect of each of the 7
components of Yokukansan on neuronal death caused by TG
using the N2a cell line. Cnidii Rhizoma (Senkyu), Hoelen
(Bukuryo) and Angelicae Radix (Toki) significantly decreased cell
death caused by TG, and Bupleuri Radix (Saiko) showed some
neuroprotective effect against TG (P=0.054) (Figure 2A). How-
ever, the other components of Yokukansan (Atractylodis Lanceae
Rhizoma (Soujutsu), Glycyrrhizae Radix (Kanzo) and Uncariae
Uncis Cum Ramulus (Chotoko)) failed to inhibit cell death caused
by TG (Figure 2A and data not shown). When using the human
neuroblastoma cell line SK-N-SH, Senkyu and Saiko induced a
significant reduction in neuronal death caused by TG (Figure 2B).
However, the other components of Yokukansan did not show any
neuroprotective effect against TG. Senkyu was the most potent
inhibitor of neuronal cell death following TG-induced toxicity in
both N2a and SK-N-SH cells. Therefore, our subsequent analysis
focused on the effect of Senkyu on neuronal death caused by ER
stress.
Senkyu and Yokukansan reduce neuronal toxicity caused
by the FAD-linked PS1 mutation
Previously, we demonstrated that mutations in PS1 increase
vulnerability to ER stress by altering the signaling pathway. We
stably transfected SK-N-SH cells with complementary DNA
constructs encoding for wild-type PS1 and PS1 with a deletion
of exon 9 (DE9), which is one of the FAD-linked mutations. As
shown in Figure 3A, the addition of TG induced a greater cell
death rate in cells expressing the mutant PS1 when compared with
cells expressing the wild-type protein. In addition, pretreatment
with Yokukansan reduced cell death to wild type levels in TG
treated cells expressing DE9. Moreover, Senkyu inhibited cell
toxicity following TG treatment in a concentration-dependent
manner, resulting in levels similar to those seen in dimethyl
sulfoxide (DMSO)-treated cells (Figure 3B). These results indicate
Figure 1. Yokukansan reduces ER stress-induced neuronal cell death. Cell toxicity in N2a cells was measured based on morphological
changes. Quantitative data are expressed as the mean 6 SEM for at least three independent experiments. The P value was compared with the control
and calculated by Student’s T test. (A) Cell death was measured 6.5 h after 1 mM TG or DMSO (control) exposure with or without 1.5 h of
pretreatment with 400 mg/ml Yokukansan. (B) Cell death was measured 6 h after hypoxia exposure and 5 h after 0.1 mM STS exposure with or
without 1.5 h of pretreatment with 400 mg/ml Yokukansan. Non treated cells were used as the control. (C) Cell death was measured 6.5 h after 1 mM
TG exposure with 1.5 h of pretreatment with the indicated concentration of Yokukansan.
doi:10.1371/journal.pone.0013280.g001
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by the AD-linked mutation through the effect of Senkyu.
Senkyu and Yokukansan reduce the vulnerability to ER
stress by altering the unfolded protein response (UPR)
signaling pathway
Normal cells respond to ER stress by increasing the transcrip-
tion of genes encoding for the ER-resident chaperons such as
GRP78/Bip, GRP94 and PDI, which facilitate protein folding
(unfolded protein response). An increase in GRP78/Bip expression
leads to cell survival. However, ER stress can also induce CHOP
expression and activation of the JNK pathway, which induce cell
death. Therefore, to determine the molecular mechanism of the
neuroprotective effect of Senkyu and Yokukansan against ER
stress, we examined the basal expression levels of GRP78/Bip and
the expression levels of mRNA encoding for CHOP following TG
toxicity after Senkyu or Yokukansan treatment. Both Senkyu and
Yokukansan upregulated GRP78/Bip expression when compared
with the no treatment control (Figures 4A and 4B). By contrast,
both Senkyu and Yokukansan treatment significantly reduced
CHOP expression when compared with cells treated with TG
alone (Figures 4C and 4D).
Senkyu and Yokukansan inhibit the activation of
caspase-4, an ER stress-specific apoptotic protease
Caspase-4 has been shown to be involved in ER stress-induced
neuronal cell death and in the pathogenesis of AD [18,19]. We have
shown that Yokukansan and Senkyu reduce ER stress-induced
neuronal cell death (Figures 1, 2, 3 and 6). Therefore, we examined
the effect of Yokukansan and Senkyu on the activation of caspase-4.
As shown in Figures 5A and 5B, both Senkyu and Yokukansan
inhibited the cleavage of caspase-4. Thus, the protective effect of
Yokukansan and Senkyu againstERstresscan bepartially attributed
to the inactivation of caspase-4 as well as regulation of the UPR.
Figure 2. Cnidii Rhizoma (Senkyu), a component of Yokukansan, has potent protective effects against ER stress- induced neuronal
toxicity. N2a cell toxicity and SK-N-SH cell viability was measured based on morphological changes and the WST-1 assay, respectively. Quantitative
data are expressed as the mean 6 SEM for at least three independent experiments. The P value was compared with the control and calculated by
Student’s T test. (A) Cell death was measured 20 h after 1 mM TG exposure with 1.5 h pretreatment with 200 mg/ml of each of the indicated
components of Yokukansan. (B) Cell viability was measured 3 h after 3 mM TG exposure with 1.5 h pretreatment with 200 mg/ml of each of the
indicated components of Yokukansan. Cells incubated with TG without any pretreatment were used as a control.
doi:10.1371/journal.pone.0013280.g002
Figure 3. Senkyu and Yokukansan reduce neuronal toxicity caused by the FAD linked PS1 mutation. Cell viability of SK-N-SH cells
expressing PS1 WT or PS1DE9 was measured using the WST-1 assay. Quantitative data are expressed as the mean 6 SEM for at least three
independent experiments. The P value was compared with the control (DMSO treated cells) and calculated by Student’s T test. (A) Cell viability was
measured 3 h after 4 mM TG exposure with or without a 1.5 h pretreatment with 400 mg/ml of Yokukansan. (B) Cell viability of cells expressing
PS1DE9 was measured 3 h after 2 mM TG exposure with a 1.5 h pretreatment with Senkyu at the indicated concentrations (0, 25, 50, 100, 200 mg/ml).
doi:10.1371/journal.pone.0013280.g003
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ER stress
Our results indicate that Yokukansan induces resistance against
ER stress by regulating the UPR and apoptotic pathway,
particularly following Senkyu treatment, one of the components
of Yokukansan. To confirm our results, we examined the effect of
Senkyu-free Yokukansan, which contains all components except
Senkyu. The Senkyu-free Yokukansan did not improve cell
viability (Figure 6). These results show that Senkyu is important
for survival during ER stress-induced toxicity. To determine how
Senkyu induces its neuroprotective effect, we screened the contents
of Senkyu as shown in Figure S1. As a result, we identified two
potent candidates, ferulic acid and coniferyl ferulate (Figure S2).
Ferulic acid, a plant constituent, has been reported to be a strong
free radical scavenger with an antioxidant capacity [20]. In
addition, ferulic acid has many pharmacological effects such as
anti-inflammatory, anticancer, anti-diabetic, anti-atherogenic and
neuroprotective [21–25]. Furthermore, ferulic acid has been
reported to be protective against amyloid b protein toxicity
[26,27]. Thus, we focused on ferulic acid. To elucidate the
function of ferulic acid, we monitored the effect of ferulic acid
pretreatment on cell viability following ER stress. Ferulic acid was
neuroprotective against ER stress in a concentration-dependent
manner and provided similar protection to that of Yokukansan- or
Senkyu-pretreated cells (Figure 6). In addition, we confirmed this
result by treating cells with a mixture of ferulic acid and Senkyu
free Yokukansan (Figure 6).
Effect of Yokukansan, Senkyu and Ferulic acid on the UPR
We have shown that induction of GRP78/Bip and reduction of
CHOP following pretreatment with Yokukansan or Senkyu
reduces cell toxicity caused by ER stress. Therefore, we examined
Figure 4. Senkyu and Yokukansan reduce susceptibility to ER stress by altering the unfolded protein response (UPR) signaling
pathway. (A and B) SK-N-SH cells were treated with Senkyu or Yokukansan (200 mg/ml) for 6.5 h. Cells were lysed and western blot analysis was
performed using an anti-Bip or anti-b-actin primary antibody (A). Quantitative data were obtained by densitometry of the bands. Data are expressed
as the mean 6 SEM for at least three independent experiments (shown as a ratio of the control). The P value was compared with the control and
calculated by Student’s T test (B). (C and D) SK-N-SH cells were treated with 1 mM TG with or without a 1.5 h pretreatment with Senkyu or Yokukansan
(200 mg/ml). The expression of CHOP mRNA and GAPDH mRNA were detected by RT-PCR (C). Quantitative data were obtained by densitometry of the
bands. Data are expressed as the mean 6 SEM for at least three independent experiments (shown as a ratio of the control). The P value was
compared with the control and calculated by Student’s T test (D).
doi:10.1371/journal.pone.0013280.g004
Figure 5. Senkyu and Yokukansan inhibit the activation of
caspase-4. (A and B) SK-N-SH cells were treated with 2 mM TG for 3 h
with or without a 1.5 h pretreatment with Senkyu (200 mg/ml) or
Yokukansan (200 mg/ml). Cells were lysed and western blot analysis was
performed using an anti-caspase-4/TX or anti-b-actin antibody (A).
Quantitative data were obtained by densitometry of the bands. Data
are expressed as the mean 6 SEM for at least three independent
experiments (shown as a ratio of the control). The P value was
compared with the control and calculated by Student’s T test (B).
doi:10.1371/journal.pone.0013280.g005
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and CHOP. Pretreatment with ferulic acid increased the mRNA
expression level of GRP78/Bip. A similar result was observed
following pretreatment with Yokukansan or Senkyu (Figures 4A, B
and 7A). In addition, CHOP induction, caused by ER stress, was
reduced following pretreatment with ferulic acid, as was seen
following pretreatment with Yokukansan or Senkyu (Figure 4C, D
and 7B). These results suggest the involvement of ferulic acid in
the regulation of the UPR signaling pathway.
Discussion
Recently, several clinicians have observed the effectiveness of
Yokukansan, a traditional Japanese medicine, in the treatment of
the BPSD and in cognitive impairment of AD [1–3]. However, the
molecular mechanism remains unclear. In this study, we examined
the effect of Yokukansan on cell death caused by TG, STS or
hypoxia. Yokukansan reduced the cell death caused by TG and
hypoxia, both of which induce ER stress via abnormal Ca
2+
homeostasis, but were unable to protect against neural toxicity
caused by STS, a mitochondrial stress inducer. These results
suggest that Yokukansan may not be effective against mitochon-
drial stress related toxicity, but on ER stress related cell toxicity
(Figure 1). In addition, recent studies have reported that
Yokukansan has preventive or inhibitive effects against the
development of memory disturbance, BPSD-like behaviors and
neurodegeneration, all of which are observed in thiamine deficient
rodents because of ER stress due to thiamine deficicency [28–30].
These reports support our hypothesis that Yokukansan may play
an important role against ER stress.
Yokukansan consists of several components. Therefore, it was
important to determine which components were effective against
ER stress. Thus, we investigated the effect of each component on
TG induced cell death. As shown in Figure 2, Bukuryo and Toki
reduced cell death in N2a cells, but not in SK-N-SH cells; Saiko
inhibited cell death in SK-N-SH cells, but not that of N2a cells;
only Senkyu rescued both N2a and SK-N-SH cells from TG-
induced cell toxicity. Such differences in effects on the cell death
observed following Bukuryo, Toki and Saiko pretreatment may be
due to differences in the exposure time and concentration of TG
or differences between the cell lines. Nevertheless, we focused on
Senkyu because it was the only component that reduced cell death
under both conditions.
As mentioned previously, our results provide strong evidence
that Senkyu, a component of Yokukansan, protects against ER
stress-induced neuronal cell death, particularly against ER-stress
caused by intracellular calcium homeostasis abnormalities
(Figure 1, 2, 3 and 6). In addition, pretreatment with Senkyu
upregulated GRP78/Bip expression and down-regulated CHOP
expression caused by ER stress (Figure 4). GRP78/Bip is known to
protect cells from cell death caused by ER stress [13–16], while
CHOP induces cell death during ER stress [16,17]. Thus, Senkyu
may inhibit ER stress-induced neuronal cell death via regulation of
the UPR and the apoptotic cascade. We also examined the effect
of Senkyu and Yokukansan on neuronal cell death caused by the
down-regulation of the UPR signaling pathway as a result of FAD-
linked PS1 mutations [7,8]. As shown in Figure 3, both
Yokukansan and Senkyu improved the viability of cells under
TG stimulation. In addition, we elucidated that Yokukansan and
Figure 6. Ferulic acid, a component of Cnidii Rhizoma (Senkyu),
has potent protective effects against ER stress-induced
neuronal toxicity. Cell viability of SK-N-SH cells was measured using
the WST-1 assay. Quantitative data are expressed as the mean 6 SEM
for at least three independent experiments. The P value was compared
with the control (DMSO treated cell) and calculated by Student’s T test.
Cell viability was measured 3 h after 3 mM TG exposure with or without
a 2 h pretreatment with 200 mg/ml of Yokukansan, Senkyu-free
Yokukansan or Senkyu, with or without ferulic acid at the indicated
concentrations (0, 10, 25 mg/ml). Cells incubated with TG without any
pretreatment were used as a control.
doi:10.1371/journal.pone.0013280.g006
Figure 7. Ferulic acid, Senkyu and Yokukansan reduce susceptibility to ER stress by altering the unfolded protein response (UPR)
signaling pathway. (A) SK-N-SH cells were treated with ferulic acid at the indicated concentrations (0, 10, 25 mg/ml) for 2 h. (B) SK-N-SH cells were
treated with 1 mM TG with or without a 2 h pretreatment with ferulic acid at the indicated concentrations (0, 10, 25 mg/ml). (A, B) The expression of
GRP78/Bip (A), CHOP (B) and GAPDH (A, B) mRNA were detected by RT-PCR. Quantitative data were obtained by densitometry of the bands. Data are
expressed as the mean 6 SEM for at least three independent experiments (shown as a ratio of the control). The P value was compared with the
control and calculated by Student’s T test.
doi:10.1371/journal.pone.0013280.g007
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stress (Figure 5). Thus, the reduction of ER stress-induced cell
death could be attributed to the inactivation of caspase-4 and
regulation of the UPR signaling pathway. These findings suggest
that Yokukansan or Senkyu alone may be an effective candidate
for the treatment of AD.
Based on these findings, we proceeded to screen the contents of
Senkyu and Yokukansan to determine their function. As a result,
we found ferulic acid, which has been shown to be protective
against amyloid b toxicity and oxidative stress [26,27]. As shown
in Figure 6, similar to Yokukansan and Senkyu, ferulic acid
reduced cell death following ER stress. Furthermore, ferulic acid
regulated the expression levels of GRP78/Bip and CHOP
(Figure 7). These findings indicate that the protective effects of
Yokukansan and Senkyu are due to ferulic acid.
We also observed that long term treatment or a high dose of
Yokukansan had a neurotoxic effect on cultured neuronal cells
(Figure 1C) and that some components of Yokukansan (Kanzo and
Chotoko) also had the same effect with respect to neurotoxicity
(Figure S3). However, longer exposure to Senkyu or ferulic acid
did not induce neurotoxicity (data not shown). These data indicate
that Senkyu or ferulic acid would be more clinically advantageous
in terms of safety.
Several studies have reported that Chotosan, another traditional
Japanese medicine, is also effective against amyloid b toxicity [31–
33]. Similar to Yokukansan, the components of Chotosan, which
include Chotoko, Bukuryo and Kanzo, activate neprilysin and
insulin degrading enzyme (IDE), both of which are proteases of the
amyloid b protein [33]. Given that Chotosan does not contain
Senkyu, it is possible that some of the neuroprotective effects seen
with Yokukansan following amyloid b toxicity could be attributed
to the other components of Yokukansan. However, the presence of
ferulic acid in Yokukansan does partially explain the neuropro-
tective effect observed following amyloid b protein toxicity
[26–27]. Considering the following results: 1: A high dose of
Yokukansan causes neural toxicity, but a high dose of Senkyu or
ferulic acid does not show any toxicity (Figures 1C and 3B, Figure
S3 and data not shown), 2: Senkyu reduces cell death following
PS1 mutations [7,8] (Figure 3), 3: Senkyu and ferulic acid reduce
cell death caused by Ca
2+-related ER stress, which could be
induced by amyloid b protein [34,35] (Figures 2 and 6), 4: Senkyu
inhibits the activation of caspase-4 under ER stress, which could
lead to neural death [18,19] (Figure 5), 5: Senkyu and Ferulic acid
regulate the UPR signaling pathway, which is activated by
amyloid b protein [36] (Figures 4 and 7), 6: Ferulic acid prevents
cell death due to amyloid b protein toxicity [27] and also induces
resistance to amyloid b1-42 toxicity in the brain [26]; Senkyu or
ferulic acid alone may be suitable drugs for AD therapy because
both medicines inhibit ER stress following amyloid b toxicity
[7,8,18,19,34–36].
At present, the therapeutic drugs available for AD include
cholinesterase inhibitors and NMDA-receptor antagonists. How-
ever, their therapeutic effect is not significant [37–40]. A number
of trials to develop effective drugs for AD have been performed
based upon the amyloid b hypothesis or tau hypothesis [41–46].
However, the development of a truly effective treatment for AD is
far away.
It has been reported that neuronal death observed in AD is
related to ER stress [4–12,18,19]. In this study, we used TG as an
ER stressor. TG, a highly lipophilic sesquiterpene lactone, is
broadly used as a selective inhibitor of sarcoplasmic reticulum
calcium-ATPase (SERCA), which pumps calcium from the cytosol
into the lumen of the ER in mammalian cells. TG-mediated
irreversible inhibition of ER calcium-ATPases can also cause the
induction of calcium leakage from the ER to the cytoplasm,
further facilitating the depletion of calcium within the ER,
resulting in an increase in cytoplasmic calcium levels [47]. Long-
term elevation of intracellular calcium can induce ER stress due to
misfolded protein accumulation [48,49]. Our results show that
Senkyu and Yokukansan were protective against TG toxicity
(Figures 1, 2, 3 and 6). This study has shown that ferulic acid,
Senkyu and Yokukansan could be potential drugs for the
treatment of AD and sheds some light for the development of
new AD therapies.
Materials and Methods
Yokukansan, its components and Senkyu-free
Yokukansan
Yokukansan (TJ-54) consists of Sojutsu (Atractylodes Lancea
rhizome), Bukuyo (Hoelen), Senkyu (Cnidii Rizoma), Chotoko
(Uncariae Uncis Cum Ramulus), Toki (Angelicae Radix), Saiko
(Bupleuri Radix) and Kanzo (Glycyrrhizae Radix). Yokukansan is
extracted from a mixture of dried plants as follows; 4 g of Sojutsu,
4 g of Bukuryo, 3 g of Senkyu, 3 g of Toki, 2 g of Saiko, 1.5 g of
Kanzo and 3 g of Chotoko were added to 700 ml of distilled water
and boiled for 1 hour, filtered, and then concentrated to 300 ml.
On the other hand, to prepare Senkyu-free Yokukansan, the same
extraction-method and amount of Soujutsu, Bukuyo, Chotoko,
Toki, Saiko and Kanzo were used. Yokukansan, components of
Yokukansan and Senkyu-free Yokukansan were kindly provided
by Tsumura & Co. (Tokyo, Japan).
Chemicals and antibodies
We used the following antibodies: anti–Bip mAb (Cell Signaling
Technology, Beverly, MA), anti-caspase-4/TX mAb (4B9; MBL
International Corporation, Nagoya, Japan), monoclonal anti-b
actin antibody (Chemicon, Temecula, CA) and HRP-conjugated
anti–mouse IgG antibody (Cell Signaling Technology). The
chemical reagents used in this experiment were thapsigargin
(TG), staurosporine (STS) (Sigma-Aldrich, St. Louis, Mo) and
ferulic acid (LKT Laboratories, Inc., St. Paul, MN).
Cell Culture
SK-N-SH human neuroblastoma cells were obtained from the
Riken Cell Bank (Tsukuba, Japan). Neuro-2a mouse neuroblasto-
ma cells (N2a cells) were obtained from ATCC (Manassas, VA).
Human neuroblastoma SK-N-SH cells and Mouse neuroblastoma
N2a cells were cultured in DMEM (Sigma) containing 10% (v/v)
fetal bovine serum and incubated in a humidified chamber at
37uC with a 5% CO2 atmosphere according to previous
experiments [7–12]. SK-N-SH neuroblastoma cell lines stably
expressing wild-type PS1 (PS1 WT cells) or PS1DE9 (PS1DE9
cells), which have been described previously [7], were cultured
similarly to SK-N-SH cells.
Cell viability assay based on morphological changes
Cell toxicity in N2a cells was measured on the basis of
morphological changes observed by phase contrast microscopy
or nuclear changes detected by fluorescence microscopy after co-
staining cells with 10 mM Hoechst 33342 and 10 mM propidium
iodide (PI). Hence, nuclear fragmentation was detected by
Hoechst-positive staining and nuclear collapse was detected by
PI-positive staining. Double positive cells were considered dead
cells. Staining was measured independently in 4 fields and at least
300 cells were counted. Data are expressed as the mean 6 SEM
for at least three independent experiments.
Yokukansan and ER Stress
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SK-N-SH cells, PS1 WT cells, or PS1DE9 cells (3610
3) were
plated onto 96-well plates 36 h before cell viability was
determined. Prior to performing the assay, cells were pretreated
for 1.5 h with Yokukansan, or with every component of
Yokukansan, at the indicated concentrations followed by the
addition of each insult (TG or STS) for 3 h. Following insult
exposure, cells were washed twice with phosphate buffered saline
(PBS) and cultured with DMEM (D1145, SIGMA) and WST-1
mixed medium for 3 hours. WST-1 was measured at an
absorption of l450 nm – l650 nm. Data are expressed as the
mean 6 SEM for at least three independent experiments.
Western blot analysis
Treated cells were washed twice with PBS, harvested and lysed
in TNE buffer (10 mM Tris-HCl, pH 7.8, 1 mM EDTA and
150 mM NaCl) containing 1% (v/v) NP-40 and protease inhibitor
cocktail (Roche, Sydney, Australia). Equal amounts of protein
were subjected to 12% (v/v) SDS-PAGE for GRP78/Bip, caspase-
4o rb actin and transferred to PVDF membrane (Millipore,
Bedford, MA). The membrane was blocked with 5% (w/v) skim
milk and incubated with primary antibody, followed by incubation
with an HRP-conjugated secondary antibody. Proteins were
visualized with an ECL detection system (Amersham Biosciences,
Piscataway, NJ).
Exposure to hypoxia
For the hypoxic insult, cells were exposed to hypoxia for 6 h
using an incubator equipped with a hypoxic chamber that
maintained a humidified atmosphere with low oxygen tension (8
Torr) as described previously [9,11,12].
RT-PCR
Total RNA was extracted from cultured SK-N-SH cells treated
with the indicated reagents using the High Pure RNA Tissue Kit
(Roche).The cDNA was synthesized from total RNA using the
High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems). Oligonucleotide sequences used for PCR were as
follows; For GRP78/Bip, forward: 59-agcctggcgacaagagtg-39,
reverse: 59-tccttgggcagtattggatt-39; For CHOP, forward: 59-
gcgcatgaaggagaaagaac-39, reverse: 59-ccaattgttcatgcttggtg-39; For
GAPDH, forward: 59-ccactcctccacctttgacg-39, reverse; 59-
caccctgttgctgtagccaa-39.
Extraction of contents from Senkyu
Cnidii Rhizoma (Senkyu, 100 g) was powdered and extracted
with hot water (500 mL, reflux, 1 h 62). The water solution was
concentrated under reduced pressure to obtain a water extract.
The crude water-extract (100 mg) was dissolved in PBS (10 mL),
and extracted for 10 min in an ultrasonic water bath. The
extraction was repeated twice. The extracted solutions were
combined and centrifuged at 10000 rpm for 10 min. The
supernatant was recovered and diluted to the appropriate
concentration with assay medium.
Supporting Information
Figure S1 Screening of contents of Senkyu. Extracts of Senkyu
were divided into #1-6 fractions. We preliminary checked the
effect of each fraction (#1-6) against the neural toxicity of TG by
using SK-N-SH cells. Fractions #1-5 did not show any protective
effect under TG stimulation, but fraction #6 showed a protective
effect against TG-induced ER stress.
Found at: doi:10.1371/journal.pone.0013280.s001 (0.61 MB
PDF)
Figure S2 List of contents contained in fraction #5 and #6
Found at: doi:10.1371/journal.pone.0013280.s002 (0.68 MB EPS)
Figure S3 Cell toxicities of Yokukansan and its components.
Cell toxicity of N2a cells was measured based on morphological
changes. Cell death was measured 24 h after treatment with
Yokukansan or each of the indicated components of Yokukansan
(200 mg/ml). Non treated cells were used as a control. Quantita-
tive data are expressed as the mean 6 SEM for at least three
independent experiments. The P value was compared with the
control and calculated by Student’s T test.
Found at: doi:10.1371/journal.pone.0013280.s003 (0.68 MB EPS)
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